 Atripla efavirenzemtricitabinetenofovir disoproxil fumarate and Stribild elvitegraviremtricitabinetenofovir disoproxil fumaratecobicistat are 2 FDA-approved one pill once a day combination antiretroviral medications given for the treatment of HIV. Both have a common nucleoside reverse transcriptase inhibitor NRTI backbone of tenofovir TDF and emtricitabine FTC, but differ in the 3rd medication contained in the pill. Atripla contains a non-nucleoside reverse transcriptase NNRTI drug efavirenz EFV while Stribild elvitegraviremtricitabinetenofovir disoproxil fumaratecobicistat contains an integrase inhibitor elvitegravir with the drug cobicistat inactive against HIV but designed to simply boost the level of elvitegravir. 